Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment

SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2 clinical trial evaluating the safety and efficacy of oral torezolid (TR-701), its investigational antibiotic for the treatment of severe complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, especially drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The study achieved its primary goals of establishing safety and efficacy in all doses evaluated.

In the randomized, double-blind, dose-ranging study conducted at eight centers in the U.S., torezolid was administered orally at doses of 200, 300 or 400 mg once-daily for five to seven days of treatment. Of the 188 patients who received drug, 164 (87%) were clinically evaluable at the test-of-cure visit. The overall cure rates of clinically evaluable patients for severe abscesses, cellulitis and wound infections were 96%, 97% and 90%, respectively. Clinical outcomes were not affected by the size of lesions. Clinical cure rates by dose in the clinically evaluable population were 98%, 94% and 94% for the 200, 300 and 400 mg doses, respectively. In the group of microbiologically evaluable patients (133, 71%), clinical cure was achieved in 100%, 93% and 96% of patients receiving 200, 300 or 400 mg doses, respectively. There were no clinical relapses at the late follow-up visit 21-28 days post treatment. Highlighting the growing problem of drug resistance in the community, MRSA was the primary pathogen in 72% of the microbiologically evaluable patients.

"I was impressed by the rapid clinical effect of oral torezolid in curing severe skin infections caused by MRSA and other gram-positive pathogens," said Dr. Joseph Surber, Chief Medical Officer, Southeas
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... and accredited investors for a registered direct placement ... and 3.35 million common stock purchase warrants for ...
(Date:7/27/2015)... --  DocResponse was ranked the most accurate ... peer-reviewed study , "Evaluation of symptom checkers for ... the July issue of The British Medical Journal ... researchers determined that performance of online symptom checkers ... first in standardized patient evaluations more often than ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7lz2fk/intraoperative ) has ... by Type (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) , ... Forecast to 2019" report to their offering. ... value of $2.1 Billion by 2019 from $1.8 Billion ... forecast period. The intraoperative imaging market ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
... 17, 2012  Boston Scientific Corporation (NYSE: BSX ... market launch of the Epic™ Vascular Self-Expanding Stent System.  ... in patients with iliac artery stenosis, a form of ... by insufficient blood flow.  "The Epic ...
... RARITAN, N.J., May 17, 2012 Janssen Pharmaceuticals, ... Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release ... providing pain management among adults with chronic moderate ... of the study were presented at the 31st ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 2Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 3Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 4Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
(Date:7/27/2015)... ... , ... On July 14, 2015, Harper’s Bazaar Magazine in an article titled ... such as stretch marks , fine lines , and acne scars ... listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is pointed out ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges ... of the foster care system to get into and complete college. , The ... introduced at an event today with partners from across the valley. , The initiative ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... Calcium Propionate industry is a professional and in-depth research report. The report ... chain structure, international market analysis etc. This report covers the global (US, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Throughout its 20 ... premier doctors and medical providers working on a lien basis. As the personal ... wide range of providers from chiropractors, to orthopedists, to pain management physicians, to psychologists ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2
... Sept. 9 As the nation awaits President Obama,s address ... The Philanthropic Collaborative (TPC) sent today a letter to the ... community foundations in the field of health. , , ... in the social and economic effectiveness of health-related philanthropic activities. ...
... that the sexual transmitted infection known as Trichomonas ... prostate cancer in a study published online September 9 ... . Jennifer Rider Stark, ScD, of the department ... in Boston, and colleagues conducted a case-control study nested ...
... , , , WASHINGTON, Sept. ... guest of President Barack Obama tonight for the President,s historic speech ... nation. , , As Co-Chair of the ... spearheading a bold campaign encouraging mayors around the country to urge ...
... Imaging technology might advance treatment of psychotic disorders, researchers ... technology has helped researchers pinpoint the part of the ... as schizophrenia begin, a new study says. , The ... in their early stages and help scientists develop more ...
... Republican Congressman Slated to Oppose President Obama,s Health Care Plan ... , , WASHINGTON, Sept. 9 Public ... Charles Boustany (R-La.) and the expected opposing remarks he will deliver ... session of Congress on health care reform. , , ...
... , , , KEYSTONE TREATMENT AND ... SIMILAR EVENTS TO FOLLOW AT CANTON AT 1 PM: , ... Media welcome at both locations , , SIOUX ... Sioux Falls, S.D. will be the 2009 national headquarters at 11 AM Wednesday, ...
Cached Medicine News:Health News:In Letter to President, TPC Highlights Foundation Grants in Health 2Health News:In Letter to President, TPC Highlights Foundation Grants in Health 3Health News:JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer 2Health News:Mayor Gavin Newsom to Be President Obama's Guest for Healthcare Reform Speech to the Nation 2Health News:Brain Scans Could Help Spot Schizophrenia Earlier 2Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:Wed., Sept. 16, 11 AM News Conference: Sioux Falls' Keystone Treatment Center Is National HQ to Lead 100 Locations Nationwide in Balloon Liftoff Celebrating Recovery Against New Wave of Drug Abuse; Former U.S. Drug Czar/4-Star Gen. Barry McCaffrey, Lieute 2
... The REFLEXION 1st MPJ IMPLANT SYSTEM ... the primary reconstruction of the 1st metatarsal ... traumatic arthritis or revision of a previous ... achieve three goals: pain relief, superior function ...
... The hands play an important part in ... impairments and rheumatic changes can cause severe ... of the finger-joint prostheses was to produce ... the natural function as nearly possible.,The cementless ...
... The OSTEOMED 3.0/4.0mm CANNULATED SCREW SYSTEM ... Orthopedic Hand surgeon and Podiatrist, can be ... fusions. The system features two simplified ... Both screw sizes utilize one unique set ...
... the lower extremity for prepping before hip or ... procedures and particularly helpful for supporting the leg ... By holding the foot/ankle in an externally rotated ... which helps eliminate the need for manual support.,The ...
Medicine Products: